New combination aims to save bladders in Muscle-Invasive cancer
NCT ID NCT05531123
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study tests a treatment plan for people with muscle-invasive bladder cancer who want to avoid bladder removal. Participants receive chemotherapy plus an immunotherapy drug called tislelizumab, followed by a tailored course of radiation therapy. The goal is to see if this combination can control the cancer while keeping the bladder intact.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of tislelizumab (an immunotherapy drug), gemcitabine and cisplatin (chemotherapy drugs), and modified hypofractionated radiation therapy
- What this could lead to
- If successful, this approach could offer a way to treat muscle-invasive bladder cancer without removing the bladder, preserving quality of life while controlling the disease.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. There are risks from chemotherapy, radiation, and immunotherapy, including side effects and the chance the cancer may still return.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could detect bladder Cancer's return — a trial puts it to the test
- Can removing bladder tumors in one piece improve cancer outcomes?
- Can an AI agent match expert urologists? a major test begins
- Can a hybrid surgical technique better remove large bladder tumors?
- Can an AI camera on a catheter spot bladder cancer better than standard scopes?
- Bladder cancer breakthrough? new combo aims to save the bladder